ARS Pharmaceuticals, Inc. (SPRY) Spending and interest coverage
- R&D / revenue · 12 months: Value 13.02%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 26.72%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 13.02% | Research and development expense / revenue. Period ending 2026-06-30. $15.23M ÷ $116.93M × 100 ≈ 13.02% |
| Stock-based compensation / revenue · 12 months | 26.72% | Share-based compensation / revenue. Period ending 2026-06-30. $31.24M ÷ $116.93M × 100 ≈ 26.72% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 15.23M USD | Research and Development Expense |
| Revenue | 116.93M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 31.24M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -216.27M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.23M | $116.93M | $31.24M | $-216.27M | (m) | 13.02% | 26.72% | (m) | (m) |
| 2026-03-31 | $14.56M | $98.99M | $24.22M | $-202.42M | (m) | 14.71% | 24.47% | (m) | (m) |
| 2025-12-31 | $13.18M | $84.28M | $22.09M | $-179.45M | (m) | 15.64% | 26.22% | (m) | (m) |
| 2025-09-30 | $12.77M | $142.77M | $20.62M | $-90.79M | (m) | 8.94% | 14.44% | (m) | (m) |
| 2025-06-30 | $14.44M | $112.34M | $18.52M | $-59.34M | (m) | 12.85% | 16.49% | (m) | (m) |
| 2025-03-31 | $17.30M | $97.12M | $16.52M | $-27.07M | (m) | 17.81% | 17.01% | (m) | (m) |
| 2024-12-31 | $19.58M | $89.15M | $14.53M | $-3.08M | (m) | 21.96% | 16.30% | (m) | (m) |
| 2024-09-30 | $19.96M | $2.57M | $12.55M | $-60.51M | (m) | 777.14% | 488.67% | (m) | (m) |
| 2024-06-30 | $18.54M | $500.00K | $11.57M | $-56.74M | (m) | 3707.20% | 2313.40% | (m) | (m) |
| 2024-03-31 | $18.95M | $10.00K | $10.30M | $-62.00M | (m) | 189480.00% | 103000.00% | (m) | (m) |
| 2023-12-31 | $20.27M | $30.00K | $9.23M | $-67.52M | (m) | 67553.33% | 30783.33% | (m) | (m) |
| 2023-09-30 | $21.57M | $30.00K | $11.72M | $-72.74M | (m) | 71906.67% | 39066.67% | (m) | (m) |
| 2023-06-30 | $22.46M | $219.00K | $9.57M | $-61.39M | (m) | 10257.08% | 4370.32% | (m) | (m) |
| 2023-03-31 | $19.50M | $673.00K | $7.83M | $-47.13M | (m) | 2898.22% | 1163.30% | (m) | (m) |
| 2022-12-31 | $18.38M | $1.32M | $5.84M | $-35.52M | (m) | 1396.35% | 444.00% | (m) | (m) |
| 2022-09-30 | $53.38M | (m) | $20.28M | $-86.94M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $60.66M | (m) | $20.26M | $-90.68M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $66.16M | (m) | $19.85M | $-95.40M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $61.50M | (m) | $19.19M | $-89.58M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $24.58M | (m) | $2.64M | $-32.92M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |